Clinical Trials
Integrated Inflammatory and Nutritional Biomarkers in Metastatic Renal Cell Carcinoma Treated with Second- or Later-Line Nivolumab: A Retrospective Cohort Study
Uğraklı et alMedicina (Kaunas)

In a retrospective cohort study of 49 consecutive patients with metastatic renal cell carcinoma (mRCC) who progressed on prior tyrosine kinase inhibitor (TKI) therapy and subsequently received second- or later-line nivolumab monotherapy, baseline C-reactive protein-to-albumin ratio (CAR) and prognostic nutritional index (PNI) were evaluated alongside early C-reactive protein (CRP) kinetics and psoas muscle index. Over a median follow-up of 48.4 months (maximum 87.8 months), the cohort-wide median overall survival (OS) was 13.9 months (IQR: 5.8–36.2), with an overall intention-to-treat objective response rate (ORR) of 36.7% (18/49). Patients presenting with a low baseline CAR demonstrated a substantial survival advantage compared to those with a high baseline CAR, recording a median OS of 32.6 months versus 5.8 months (log-rank p < 0.001; Benjamini-Hochberg q = 0.003). In multivariable Cox proportional hazards modeling adjusted for International Metastatic RCC Database Consortium (IMDC) risk category, ECOG performance status, and de novo metastatic presentation, both CAR (HR: 1.029; p = 0.002) and PNI (HR: 0.893; p < 0.001) maintained independent prognostic significance. Analysis of 43 patients with complete 3-month CRP records revealed that a CRP ratio at or below the cohort median of 1.16 correlated with a significantly higher ORR compared to higher levels (54.5% vs. 23.8%; p = 0.039). Although an elevated 3-month CRP ratio trended toward shorter time-to-treatment failure (TTF), this endpoint did not meet the predefined threshold after false discovery rate correction (BH q = 0.098). The study authors noted that these single-center retrospective data require prospective multi-institutional validation before clinical implementation.
Key Takeaways
- Low baseline C-reactive protein-to-albumin ratio (CAR) was associated with significantly prolonged median overall survival compared to high baseline CAR (32.6 vs. 5.8 months; log-rank p < 0.001, BH q = 0.003).
- In adjusted multivariable analysis, baseline CAR (HR: 1.029, p = 0.002) and prognostic nutritional index (PNI; HR: 0.893, p < 0.001) independently predicted overall survival in mRCC patients receiving post-TKI nivolumab.
- Patients maintaining a 3-month C-reactive protein ratio at or below 1.16 demonstrated a significantly higher objective response rate compared to those exceeding this threshold (54.5% vs. 23.8%, p = 0.039).
Read the original sourceMedicina (Kaunas)
